January 2026 Research Update

This month added clearer separation between what changes symptoms and what changes lab markers in Fabry disease. In a large placebo-controlled trial, lucerastat lowered storage markers in blood and urine, but it did not reduce neuropathic pain over 6 months. This helps clarify that biomarker improvements and pain relief do not always move together in the short term. [1]

In the MODIFY trial, people taking lucerastat had larger reductions in plasma and urine Gb3 than those taking placebo, while pain scores were similar between groups at Month 6. Kidney function measures were also similar between groups in the randomized part of the trial, and longer-term open-label follow-up was described as exploratory. The trial also reported nausea and diarrhea more often with lucerastat, with no deaths reported. [1]

For patients, the main new point is that a therapy can measurably lower Fabry-related storage markers without clearly improving neuropathic pain over the same time window. This matters now as a more realistic picture of what outcomes may or may not change together in trials, and later as researchers work out which symptoms best reflect meaningful benefit for different people. What remains uncertain is whether the longer-term signals mentioned in open-label follow-up (including kidney-related trends) would hold up in controlled comparisons. [1]

This month, several studies focused on finding Fabry disease earlier or tracking it more precisely, often by looking beyond standard tests. The common pattern was that newer approaches (genetic methods, blood markers, symptom questionnaires, imaging, and digital pathology) may pick up signals that routine pathways can miss. At the same time, most of these tools are still in an evaluation phase, so the main change is improved understanding of what might be measurable rather than a new standard approach. [2] [3]

Two men with clear biochemical signs of Fabry disease but previously negative standard genetic testing were found to have large non-coding GLA insertions using long-read sequencing, with RNA results supporting disrupted or reduced GLA transcripts. This highlights that some people may have disease-causing changes outside the usual regions targeted by common sequencing, which can contribute to "missing" genetic explanations. The finding is based on only two patients, so it mainly strengthens the idea of expanding testing in unresolved cases rather than proving how often this occurs. [2]

A blood-based marker study reported higher circulating cell-free mitochondrial DNA in treatment-naive Fabry patients than in controls, and the marker showed good ability to separate the groups. After long-term enzyme replacement therapy, the mitochondrial-to-nuclear DNA ratio looked more similar to controls even though mitochondrial DNA levels stayed higher, suggesting the marker may reflect more than one biological process. The same study found only limited links between these DNA measures and most routine clinical markers after adjusting for age and sex. [3]

Two separate method-focused papers aimed to improve lab monitoring. One developed a way to measure antibodies against pegunigalsidase alfa (a pegylated enzyme replacement therapy) by first removing drug interference from serum, and it detected new anti-drug antibodies in one person and strong anti-PEG antibodies in another. Another validated a lab method to measure lyso-Gb3 in plasma with low detection limits, and in a small sample it perfectly separated Fabry patients from healthy controls. [4] [5]

Several studies evaluated non-invasive or workflow-based ways to spot disease features earlier. In young children followed over time, parent-completed gastrointestinal questionnaires detected symptoms more often than pediatrician notes, and one questionnaire performed better after 24 months of follow-up. A retinal vessel study found narrower retinal arterioles and reduced venular dilation in Fabry disease compared with controls, along with higher inflammatory and endothelial markers, and reported stronger links in people with certain GLA variants described as cardiac-related. [6] [7]

Kidney-focused diagnostic work also moved toward more detailed interpretation of biopsy data. An AI-based pipeline created a "ZEBRA" score to quantify foamy podocytes in kidney biopsy images and reported good discrimination of Fabry nephropathy from controls, while noting that performance and generalizability need more validation. Separately, an adult inherited metabolic disease clinic review reported that most Fabry diagnoses in their cohort came through family screening and that prior misdiagnoses were common, emphasizing how diagnostic routes affect time to recognition. [8] [9]

A Taiwanese registry for hypertrophic cardiomyopathy and related conditions (including Fabry disease) reported baseline data showing that family history was a useful clue, while common echocardiography measures and NT-proBNP were not clearly different across groups at baseline. This reinforces that Fabry-related heart thickening can look similar to other causes on common tests, which is why registries and structured diagnostic pathways are being developed. Results on longer-term outcomes are not yet available. [10]

For patients and caregivers, this month mainly adds reassurance that research is actively trying to close gaps in diagnosis and monitoring, especially for people whose results do not fit neatly into standard pathways. Some tools aim to find hidden genetic causes (long-read sequencing) or capture symptoms that may be under-recorded (parent questionnaires), while others try to make tracking more precise (lab assays for lyso-Gb3 or antibodies, retinal vessel measurements, and biopsy image analysis). What remains uncertain is how widely these approaches will work across different hospitals and populations, because many were tested in small or single-center groups, or are still being validated. [2] [6]

This month, studies added detail to the idea that Fabry disease severity varies because multiple body systems and multiple layers of biology are involved. Human observational work pointed to measurable differences in nerve function [11] , while genetic analyses suggested that variants outside the GLA coding region may influence kidney progression [12] . Lab and animal studies proposed cellular stress pathways that could modify blood vessel function [13] , offering candidate targets for future research rather than immediate clinical tools.

In a small comparison with healthy controls, Fabry patients had slower motor nerve conduction in the ulnar and peroneal nerves, and lower peroneal motor amplitude, with worse findings in men and in those with chronic kidney disease. The authors interpreted the pattern as consistent with a demyelinating component (damage to the nerve insulation) contributing to motor nerve involvement. This helps broaden the picture of Fabry neuropathy beyond pain alone, although the study was small and included patients on varied therapies. [11]

A genetic association study in 284 Fabry patients reported that two non-coding variants in SHROOM3 were linked to faster kidney function decline, even though these variants did not line up with conventional kidney biomarkers. This supports the idea that part of the difference in kidney outcomes may come from additional genes that affect kidney cell resilience, not just the primary GLA change. The work is exploratory, so it is best viewed as an early signal that needs confirmation in other cohorts. [12]

In preclinical endothelial models, GLA deficiency was linked to higher expression of Hsp70 family stress proteins in kidney blood vessel cells, along with lower activity of an enzyme involved in blood vessel relaxation and signs of nitrosative stress. When Hsp70 was inhibited in these cell models, some measures worsened and some lysosome-related changes reversed, suggesting Hsp70 may be part of a compensatory response rather than a simple "bad actor." This work is laboratory and mouse research, so it does not predict symptoms in people, but it provides testable ideas about why blood vessel problems happen in Fabry disease. [13]

A separate fly-model platform study included Fabry-related gene knockdowns and reported reduced lifespan and age- and sex-dependent movement decline, with female-predominant vulnerability noted in the Fabry models. This supports using tissue-specific models to explore how the nervous system and gut might contribute to disease features over time, and to screen potential interventions. It remains a research tool rather than evidence about patient outcomes. [14]

For patients, the main message is that researchers are getting more specific about why two people with Fabry disease can have different kidney, nerve, and blood vessel courses. Some of that variation may relate to other genes (like SHROOM3) and to measurable changes in nerve signaling and small blood vessels, which could eventually support better prediction and monitoring. Much of the mechanistic work this month is still early-stage (cell, mouse, and fly studies), so it mainly builds a roadmap for future studies rather than changing what can be concluded for an individual person today. [12] [13]

This month’s case reports collectively emphasized how Fabry disease can be missed, mimicked, or complicated by other conditions. The shared pattern was that careful re-evaluation (often including genetics and biopsy review) changed the explanation for a person’s symptoms, either by confirming an unusual Fabry presentation, identifying an additional diagnosis, or ruling Fabry out. These are individual stories, so they mainly highlight possibilities rather than typical outcomes. [15] [16]

Two reports focused on women with nonclassic or late-recognized Fabry disease. One described a 36-year-old woman initially labeled as having leukocytoclastic vasculitis, where kidney biopsy findings plus genetic testing supported Fabry disease. Another described a 72-year-old woman with end-stage kidney disease and thickened heart muscle, in whom a new likely pathogenic GLA variant was identified and tracked in family members alongside low enzyme activity and elevated lyso-Gb3. [15] [17]

One report showed how a second genetic kidney disease can speed up kidney decline in someone who also has Fabry disease. A 40-year-old woman with Fabry disease had unusually rapid kidney failure, and a re-read of her kidney biopsy plus additional genetic testing supported coexisting autosomal dominant Alport syndrome. This highlights that an unexpected course may sometimes reflect more than one condition affecting the kidneys. [18]

One report illustrated an important mimic of Fabry disease on kidney biopsy. A 17-year-old with zebra bodies (a classic-looking biopsy feature) was ultimately found to have normal alpha-galactosidase A activity and no disease-causing GLA variant, with the biopsy changes attributed to atomoxetine-related drug-induced phospholipidosis. This reinforces that biopsy appearance alone may not be enough without supportive enzyme and genetic testing. [16]

For patients and families, these reports mainly reinforce that diagnosis can be complex, especially in women or in people with atypical symptoms, and that confirmatory testing matters when findings are unclear. They also show that sometimes an unexpected disease course can have an added explanation, such as a second inherited kidney disorder or a medication-related mimic. What remains uncertain is how often these scenarios occur, because case reports describe rare or instructive situations rather than the average Fabry experience. [15] [18]

One publication this month summarized expert consensus on how Fabry disease is diagnosed, treated, and followed in children. The main change here is not a new experimental result, but a clearer attempt to standardize what experts consider reasonable across many common clinical situations. The work reported agreement on a set of recommendations after reviewing the recent literature and using a formal consensus process. [19]

The group reported reaching consensus on 57 recommendations, and these were reviewed by external experts from multiple countries. The paper does not provide new patient outcome data, but it reflects where the field currently agrees on pediatric Fabry disease care topics. [19]

For families, this type of publication may matter now by reducing inconsistency in how pediatric Fabry disease is approached across settings, even though it is not a clinical trial. It may also matter later as a reference point to compare against new evidence as it emerges. What remains uncertain from this paper alone is how these recommendations affect outcomes in real-world pediatric care, because it reports consensus rather than new results. [19]